Printer Friendly

SPECTRASCIENCE RECEIVES ORDERS FOR NEW DIAGNOSTIC SYSTEM

 MINNEAPOLIS, March 4 /PRNewswire/ -- SpectraScience, Inc., (NASDAQ:SPSC) announced today that it has received firm orders from European customers for two of its LIF(R) diagnostic systems.
 Daryl F. Yurek, chairman and chief executive officer, said the systems will be shipped in the second quarter to a private clinic and to a major medical university. Both customers have also signed annual supply contracts under which they have agreed to purchase a quantity of the company's disposable Diagnostic Guidewire(TM). Yurek said the university has also agreed to publish its experience with the system for presentation to an upcoming professional conference.
 The LIF(R) system uses laser induced fluorescence to identify and characterize coronary artery disease. SpectraScience designs, develops, manufactures and markets laser-enhanced systems for the diagnosis and treatment of cardiovascular disease. The laser diagnostic system currently is the main focus of the company's development efforts. SpectraScience is based in Minneapolis.
 -0- 3/4/93
 /CONTACT: Curt Swenson of Swenson Falker Eilertsen, 612-371-0000, for SpectraScience; or Tom Ahmann of SpectraScience, 612-559-4000/
 (SPSC)


CO: SpectraScience, Inc. ST: Minnesota IN: MTC SU:

AL -- MN013 -- 2961 03/04/93 11:53 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 4, 1993
Words:188
Previous Article:DWG SPECIAL SHAREHOLDER MEETING RESCHEDULED FOR APRIL 13, 1993
Next Article:MARKET INTELLIGENCE: INTENSIFIED REGULATION, PORTABILITY, TO DOUBLE WASTEWATER ANALYSIS MARKET, APPROACHING $900 MILLION
Topics:


Related Articles
SPECTRASCIENCE LASER DIAGNOSTIC SYSTEM USED IN SUCCESSFUL CORONARY PROCEDURE AT CLEVELAND CLINIC
SPECTRASCIENCE GETS $1.1 MILLION FROM WARRANT EXERCISE
SPECTRASCIENCE GETS TOTAL OF $3,252,998 FROM WARRANT EXERCISE
SPECTRASCIENCE INSTITUTES CASH CONSERVATION MEASURES, COMPLETING PRODUCT DEVELOPMENT ACTIVITIES
COMPANY WILL RESUME CLINICAL TRIALS AS A RESULT OF PRODUCT ENHANCEMENTS; PRODUCT COMMERCIALIZATION ANTICIPATED IN 1994; DIRECTOR RESIGNS
SPECTRASCIENCE REPORTS REDUCED LOSS FOR THIRD QUARTER
SPECTRASCIENCE REPORTS REDUCED LOSS FOR FOURTH QUARTER AND 1993 YEAR
SpectraScience Strengthens Leadership Team With Four Key Hires.
SpectraScience Announces Business Update.
SpectraScience Secures Distribution for WavSTAT(R) Cancer Diagnosis System in Germany & Austria.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters